Cadila Healthcare Ltd has reported total income of Rs.3823.1 crores during the period ended December 31, 2020 as compared to Rs.3847.5 crores during the period ended September 30, 2020.

The company reported total income of Rs.3658.2 crores during the period ended December 31, 2019.

Cadila Healthcare has posted net profit of Rs.527.20 crores for the period ended December 31, 2020 as against net profit of Rs.473.40 crores for the period ended September 30, 2020.

The company has posted net profit of Rs.373.9 crores for the period ended December 31, 2019.

For the 9 months period ended December 31, 2020, Cadila Healthcare has reported total income of Rs.11333.0 crores as compared to Rs.10570.6 crores during the 9 months period ended December 31, 2019.

The company has posted net profit of Rs.1454.6 crores for the 9 months period ended December 31, 2020 as against net profit of Rs.784.7 crores for the 9 months period ended December 31, 2019.

The company's business in India geography which comprises Human health formulations business, Consumer wellness business and Animal health business posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore. Human health formulations business in India grew by 21%, Consumer wellness business grew by 16% and Animal health business grew by 17% on a y-o-y basis during the quarter.

US formulations business registered revenues of Rs. 1,603 crore during the quarter. The company filed 10 additional ANDAs with the USFDA taking the cumulative number of filings to 410 and received 9 new product approvals (including 4 tentative approvals) from the USFDA.

During the quarter, the company launched the oral anti-diabetic agent, Dapaglyn (Dapagliflozin) in India for patients suffering from Chronic Obstructive Pulmonary Disorder (COPD). The company launched Forglyn, India's first pressurised metered dose inhaler with a combination of Long Acting Muscarinic Antagonist (LAMA) and long acting beta agonist (LABA).

Continuing its fight against COVID-19, the company received approvals to start Phase III clinical trials of Pegylated Interferon Alpha-2b in India and the approval to start Phase III clinical trials of its vaccine ZyCoV-D. The trials for the vaccine are underway and will be tested across 60 locations in 30,000 healthy adult volunteers in India.